Literature DB >> 16212898

Immunological responses against SARS-coronavirus infection in humans.

Xiaojun Xu1, Xiaoming Gao.   

Abstract

Since the outbreak of a SARS epidemic last year, significant advances have been made on our understanding of the mechanisms of interaction between the SARS coronavirus (CoV) and the immune system. Strong humoral responses have been found in most patients following SARS-CoV infection, with high titers of neutralizing Abs present in their convalescent sera. The nucleocapsid (N) and spike (S) proteins of SARS-CoV appear to be the dominant antigens recognized by serum Abs. CD4+ T cell responses against the N protein have been observed in SARS patients and an HLA-A2-restricted cytotoxic T lymphocyte epitope in the S protein has been identified. It is likely that the immune responses induced by SARS-CoV infection could also cause pathological damage to the host, especially in the case of proinflammatory cytokines. There is also evidence suggesting that SARS-CoV might be able to directly invade cells of the immune system. Our understanding on the interaction between SARS-CoV, the immune system and local tissues is essential to future diagnosis, control and treatment of this very contagious disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 16212898

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   11.530


  40 in total

1.  Success of Current COVID-19 Vaccine Strategies vs. the Epitope Topology of SARS-CoV-2 Spike Protein-Receptor Binding Domain (RBD): A Computational Study of RBD Topology to Guide Future Vaccine Design.

Authors:  Santhinissi Addala; Madhuri Vissapragada; Madhumita Aggunna; Niharikha Mukala; Manisha Lanka; Shyamkumar Gampa; Manikanta Sodasani; Jahnavi Chintalapati; Akhila Kamidi; Ravindra P Veeranna; Ravikiran S Yedidi
Journal:  Vaccines (Basel)       Date:  2022-05-25

2.  Clinical and immunological features of severe and moderate coronavirus disease 2019.

Authors:  Guang Chen; Di Wu; Wei Guo; Yong Cao; Da Huang; Hongwu Wang; Tao Wang; Xiaoyun Zhang; Huilong Chen; Haijing Yu; Xiaoping Zhang; Minxia Zhang; Shiji Wu; Jianxin Song; Tao Chen; Meifang Han; Shusheng Li; Xiaoping Luo; Jianping Zhao; Qin Ning
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

3.  Quasispecies of SARS-CoV-2 revealed by single nucleotide polymorphisms (SNPs) analysis.

Authors:  Rongsui Gao; Wenhong Zu; Yang Liu; Junhua Li; Zeyao Li; Yanling Wen; Haiyan Wang; Jing Yuan; Lin Cheng; Shengyuan Zhang; Yu Zhang; Shuye Zhang; Weilong Liu; Xun Lan; Lei Liu; Feng Li; Zheng Zhang
Journal:  Virulence       Date:  2021-12       Impact factor: 5.882

Review 4.  The Immune Responses against Coronavirus Infections: Friend or Foe?

Authors:  Arefe Vafaeinezhad; Mohammad Reza Atashzar; Rasoul Baharlou
Journal:  Int Arch Allergy Immunol       Date:  2021-05-05       Impact factor: 2.749

5.  Down-regulation of granulocyte-macrophage colony-stimulating factor by 3C-like proteinase in transfected A549 human lung carcinoma cells.

Authors:  Hsien-Hua Liao; Yao-Chen Wang; Miles Chih-Ming Chen; Hsien-Yu Tsai; Johnson Lin; Shui-Tein Chen; Gregory Jiazer Tsay; Sun-Long Cheng
Journal:  BMC Immunol       Date:  2011-02-17       Impact factor: 3.615

Review 6.  Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential.

Authors:  Melissa M Coughlin; Bellur S Prabhakar
Journal:  Rev Med Virol       Date:  2011-09-08       Impact factor: 6.989

Review 7.  The spike protein of SARS-CoV--a target for vaccine and therapeutic development.

Authors:  Lanying Du; Yuxian He; Yusen Zhou; Shuwen Liu; Bo-Jian Zheng; Shibo Jiang
Journal:  Nat Rev Microbiol       Date:  2009-02-09       Impact factor: 60.633

8.  Identification of a novel conserved HLA-A*0201-restricted epitope from the spike protein of SARS-CoV.

Authors:  Yanbo Lv; Zhihua Ruan; Li Wang; Bing Ni; Yuzhang Wu
Journal:  BMC Immunol       Date:  2009-12-03       Impact factor: 3.615

9.  Local Sustained GM-CSF Delivery by Genetically Engineered Encapsulated Cells Enhanced Both Cellular and Humoral SARS-CoV-2 Spike-Specific Immune Response in an Experimental Murine Spike DNA Vaccination Model.

Authors:  Rémi Vernet; Emily Charrier; Erika Cosset; Sabine Fièvre; Ugo Tomasello; Julien Grogg; Nicolas Mach
Journal:  Vaccines (Basel)       Date:  2021-05-10

10.  Human monoclonal antibodies against highly conserved HR1 and HR2 domains of the SARS-CoV spike protein are more broadly neutralizing.

Authors:  Hatem A Elshabrawy; Melissa M Coughlin; Susan C Baker; Bellur S Prabhakar
Journal:  PLoS One       Date:  2012-11-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.